ResearchMoz

Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

GBI Research
Published Date » 2013-07-31
No. Of Pages » 93
 GBI Research, the leading business intelligence provider, has released its latest research, “Multiple Sclerosis Therapeutics to 2019 Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth”. Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of...
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 8
2.3 Symptoms 9
2.4 Etiology 9
2.5 Pathophysiology 10
2.5.1 Blood Brain Barrier Degradation 10
2.5.2 Cellular Infiltration of the Central Nervous System 10
2.6 Co-morbidities/Complications 11
2.7 Diagnosis 12
2.7.1 McDonald Criteria 12
2.7.2 Physical Examination 13
2.7.3 MRI Scans 13
2.7.4 Lumbar Puncture 13
2.7.5 Other Diagnostic Tests 13
2.8 Prognosis 14
2.9 Treatment Efficacy 15
2.10 Treatment Options 15
2.10.1 Corticosteroids 16
2.10.2 Anti-neoplastic Drugs 16
2.10.3 Skeletal Muscle Relaxants 16
2.10.4 Pain Management in MS 17
2.11 Treatment Algorithm 17
2.12 Non-pharmacological Therapies 19

3 Therapeutic Landscape 20
3.1 Copaxone (glatiramer acetate) – Teva Pharmaceuticals 20
3.2 Betaseron (interferon beta 1b) – Bayer AG 21
3.3 Avonex (interferon beta 1a IM) – Biogen 22
3.4 Rebif (interferon beta 1a SC) – Merck Serono 23
3.5 Tysabri (natalizumab) – Biogen Idec/Elan Corporation 24
3.6 Gilenya (fingolimod hydrochloride) – Mitsubishi Tanabe and Novartis 25
3.7 Aubagio (Teriflunomide) – Genzyme Corporation and Sanofi-Aventis 26
3.8 Novantrone (mitoxantrone ) – Merck Serono 26
3.9 Conclusion 28
3.10 Unmet Need 28

4 Pipeline for Multiple Sclerosis Therapeutics 29
4.1 Overall Pipeline 29
4.2 Route of Administration 31
4.3 Molecular Targets within the MS Pipeline 32
4.4 Clinical Trials 34
4.4.1 Failure Rate of Developmental Programs 34
4.4.2 Clinical Trial Size 36
4.4.3 Clinical Trial Duration 38
4.5 Promising Pipeline Candidates 40
4.5.1 Lemtrada (alemtuzumab) – Genzyme and Bayer Schering Pharma 40
4.5.2 Tecfidera (dimethyl fumarate) – Biogen Idec 40
4.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 41
4.5.4 ocrelizumab – F. Hoffman-La Roche 42
4.5.5 daclizumab – Biogen Idec and Abbot Laboratories 42
4.5.6 firategrast – GlaxoSmithKline 43
4.5.7 Siponimod (BAF-312) – Novartis AG 44
4.6 Conclusion 44

5 Market Forecast to 2019 47
5.1 Geographical Markets 47
5.1.1 Key Developed Markets 47
5.1.2 US 50
5.1.3 Top Five EU Countries 52
5.1.4 Japan 56
5.2 Drivers and Barriers 58
5.2.1 Drivers 58
5.2.2 Barriers 59

6 Deals and Strategic Consolidations 61
6.1 Major Co-development Deals 61
6.1.1 Daiichi Sankyo Enters into an Agreement with Amplimmune 63
6.1.2 Karo Bio Enters into an Agreement with Pfizer 63
6.1.3 Proteostasis Enters into an Agreement with Elan 63
6.1.4 Lycera Enters into an Agreement with Merck 64
6.1.5 Facet Enters into an Agreement with Trubion 64
6.1.6 UCB Enters into an Agreement with Biogen 64
6.2 Major Licensing Deals 65
6.2.1 Addex Extends its Licensing Agreement with Merck 68
6.2.2 Biogen Enters into a Licensing Agreement with Acorda Therapeutics 69
6.2.3 Genzyme Enters into a Licensing Agreement with Bayer Healthcare 69
6.2.4 Novartis Enters into a Licensing Agreement with Peptimmune 69
6.2.5 Merck Serono Enters into a Licensing Agreement with Apitope Technology 69
6.2.6 Antisense Enters into a Licensing Agreement with Teva Pharmaceutical 70
6.2.7 BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly 70
6.2.8 Biotica Enters into an Agreement with Wyeth 70

7 Appendix 71
7.1 Pipeline Product Tables by Phase 71
7.2 Market Forecasting Data Tables to 2019 81
7.3 Market Definition 85
7.4 Abbreviations 85
7.5 References 86
7.6 Methodology 89
7.7 Secondary Research 90
7.8 Therapeutic Landscape 90
7.9 Epidemiology-Based Forecasting 91
7.10 Market Size by Geography 92
7.11 Pipeline Analysis 93
7.12 Contact Us 93
7.13 Disclaimer 93

List of Tables


Table 1: McDonald Criteria, Multiple Sclerosis, 2013 12
Table 2: Expanded Disability Status Scale, Multiple Sclerosis, 2013 14
Table 3: Multiple Sclerosis, Global, Market Forecast, ($bn), 2012–2019 81
Table 4: Multiple Sclerosis, US, Market Forecast, ($bn), 2012–2019 81
Table 5: Multiple Sclerosis, UK, Market Forecast, ($bn), 2012–2019 82
Table 6: Multiple Sclerosis, France, Market Forecast, ($bn), 2012–2019 82
Table 7: Multiple Sclerosis, Germany, Market Forecast, ($bn), 2012–2019 83
Table 8: Multiple Sclerosis, Italy, Market Forecast, ($bn), 2012–2019 83
Table 9: Multiple Sclerosis, Spain, Market Forecast, ($bn), 2012–2019 84
Table 10: Multiple Sclerosis, Japan, Market Forecast, ($bn), 2012–2019 84

List of Figures


Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 18
Figure 2: Multiple Sclerosis, Marketed Products Heat Map 27
Figure 3: Overall Pipeline for Multiple Sclerosis 30
Figure 4: Routes of Administration in the Pipeline 31
Figure 5: Molecular Targets of Pipeline Molecules 32
Figure 6: Molecular Targets in MS Pipeline by Phase of Development 33
Figure 7: Failure Rate of MS Clinical Trials, 2006–2013 35
Figure 8: Reasons for Clinical Trial Failure, 2006–2013 36
Figure 9: Clinical Trial Size by Product and Phase, 2006–2013 37
Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013 39
Figure 11: Multiple Sclerosis, Pipeline Product Heat Map 45
Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019 46
Figure 13: Multiple Sclerosis Market, Global, Patient Volumes (‘000) and Market Size ($bn), 2012–2019 49
Figure 14: Multiple Sclerosis Market, US, Patient Volumes (‘000), Annual Cost of Treatment ($) and Market Size ($bn), 2012–2019 51
Figure 15: Multiple Sclerosis Market, EU5, Patient Population (‘000), 2012–2019 53
Figure 16: Multiple Sclerosis Market, EU5, Annual Cost of Treatment ($), 2012–2019 54
Figure 17: Multiple Sclerosis Market, EU5, Market Size ($bn), 2013–2019 55
Figure 18: Multiple Sclerosis Market, Japan, Patient Volume (‘000), Annual Cost of Treatment ($) and Market Size ($bn), 2013–2019 57
Figure 19: Multiple Sclerosis, Co-development Deals by Geography, Value and Year, 2006–2013 61
Figure 20: Multiple Sclerosis, Co-Development Deal Frequency by Phase and Molecule Type 2006–2013 62
Figure 21: Multiple Sclerosis, Licensing Deals by Geography, Value and Year, 2006–2013 66
Figure 22: Multiple Sclerosis, Licensing Deal frequency by Phase and Molecule Type, 2006–2013 67
Figure 23: Multiple Sclerosis, Licensing Deal Value by Molecule Type and Mechanism of Action, 2006–2013 68
Figure 24: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Discovery) 71
Figure 25: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-I 72
Figure 26: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-II 73
Figure 27: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-III 74
Figure 28: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -I 75
Figure 29: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -II 76
Figure 30: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - I 77
Figure 31: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - II 78
Figure 32: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase III) 79
Figure 33: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Registration) 79
Figure 34: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Undisclosed) 80
Figure 35: Multiple Sclerosis Market, Global, GBI Research Market Sizing Model 92

Upcoming Reports:

Poland: milk market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the milk market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the milk market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Greece: market of cordage, ropes or cables of polyamides or polyesters
By - Williams and Marshal Strategy
ot least, the report presents a general overview of the economy of Greece in 2008-2012 and a forecast for its development in the medium term. The report on the cordage, ropes or cables of polyamides or polyesters market in Greece includes: Analysis and dynamics of the economy of Greece; Forecast for the development of the economy of Greece; Analysis and forecast of market volume and dynamics; Volume, dynamics and analysis of domestic production; Characteristics of market structure (by origin, by types of products, etc.); Analysis of price level and dynamics; Volume, dynamics and...
Movement Disorder Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020
By - Transparency Market Research
Movement disorders are neurological diseases and syndromes affecting the ability to generate and control movement. This disorder mainly affects brain, spinal cord and nerves throughout the body giving rise to cerebrovascular diseases, degenerative diseases of adult life, trauma, neuro-genetic diseases, developmental disorders, metabolic diseases, convulsive disorders, infectious diseases and brain tumors. According to World Health Organization (WHO), in year 2012, the U.S. health department recorded 6 million patients suffering from various movement disorders. The movement disorders that...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

British Stocks Fell Flat after Decline in Retail Sales
Apr 23, 2015  
The shares of the top British companies were left mostly unchanged on Thursday, April 23, 2015, after an unforeseen fall in the national retail sales for this month making up for an increase in the utilities shares just 2 weeks before the general election. Whereas the expectation for a single party to win an outright majority on May 7, 2015 is very low, and the experts forecasting a...
Retail Clinics Touched 10 Million Annual Visits
Apr 23, 2015  
The proliferation of retail health means Americans are visiting retail clinics more than 10 million times a year at 1,800-plus locations, yet this convenient and low cost care model accounts for just a fraction of primary care in the U.S. Manatt Health, a health care consulting firm, said retail clinics represent about 2% of “all primary care encounters” in the U.S. even with the...
China Imposes a Fine on Mercedes of US$57 million
Apr 23, 2015  
A Chinese regulator said Thursday it has fined Mercedes Benz US$57 million on price-fixing charges in a wide-ranging probe of the auto industry that has prompted complaints foreign automakers are being treated unfairly. The unit of Germany's Daimler AG was fined for violating anti-monopoly law by enforcing minimum prices dealers were required to charge for vehicles and replacement parts,...
Zinc to Surpass Gold for Personal Portfolios
Apr 23, 2015  
The precious metals such as gold are in low gear, although miners are trying to have a better look. A lot of the Oxford Club Members are trying to give a fill to their metal portfolios.  There is speculation about zinc to outperform this year. Since mid March, the metal is up by 12.9% already. The numbers are much better than gold and market estimates are it is going to go even...
Copper Traders in the World Bracing for Inventory
Apr 23, 2015  
The copper traders in the world are in a dreaded state. China which is large consumer of copper has withdrawn demand due to slowdown of building boom, and market data for the week elucidates higher volumes consumed for intermediate copper concentrates rather than the finished material which has been the mainstay of global trade. It is sign of further tough times for copper traders, as...